Kushen flavonoids induce apoptosis in tumor cells by inhibition of NF-κB activation and multiple receptor tyrosine kinase activities

Phytotherapy Research

Volumn 21, Issue 3, 2007, Pages 262-268

  Han, Jun ^a,b   Sun, Mingyu ^a,b   Cui, Yumin ^a   Wang, Tao ^a   Zhang, Weihan ^a   Guo, Mingchuan ^a   Zhou, Yuan ^a   Liu, Wei ^a   Zhang, Meifang ^a   Duan, Jifeng ^a   Xiong, Sidong ^b   Yao, Minghui ^b   Yan, Xiaoqiang ^a  

^a Hutchison Medipharma Ltd   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Flavonoids; Kushen; NF B activation; Tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KURARINONE; KUSHEN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOPHORA FLAVESCENS EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; SOPHORA; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUGS, CHINESE HERBAL; FLAVONOIDS; HUMANS; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHYTOTHERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 33947575828     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2065     Document Type: Article

References (27)

1. Baas P, Belderbos JS, Senan S et al. 2006. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. Br J Cancer 94: 625-630.
2. Coon JT, Ernst E. 2004. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 40: 491-500.
3. Herbst RS, Prager D, Hermann R et al. 2005. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899.
4. Horwitz SB. 1992. Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136.
5. Hu MJ, Zeng H, Wu YL et al. 2005. Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice. Chin J Dig Dis 6: 68-71.
6. Igney FH, Krammer PH. 2002. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288.
7. Ivan D, Niveiro M, Diwan AH et al. 2006. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol 33: 280-285.
8. Jow GM, Wu YC, Guh JH, Teng CM. 2004. Armepavine oxalate induces cell death on CCRF-CEM leukemia cell line through an apoptotic pathway. Life Sci 75: 549-557.
9. Kohn EC, Sarosy G, Bicher A et al. 1994. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24.
10. Lee CT, Wu S, Gabrilovich D et al. 1996. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 56: 3038-3041.
11. Liao PC, Lieu CH. 2005. Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells. Life Sci 76: 1623-1639.
12. Marzola P, Degrassi A, Calderan L et al. 2005. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11: 5827-5832.
13. Motzer RJ, Michaelson MD, Redman BG et al. 2006. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
14. Niho S, Kubota K, Goto K et al. 2006. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 24: 64-69.
15. Patel PH, Chaganti RS, Motzer RJ. 2006. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94: 614-619.
16. Perez EA, Livingstone AS, Franceschi D et al. 2006. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202: 623-629.
17. Pollack VA, Savage DM, Baker DA et al. 1999. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748.
18. Strumberg D. 2005. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41: 773-784.
19. Sun MY, Han J, Duan JF et al. 2006. Novel anti-tumor activities of Kushen flavonoids in vitro and in vivo. Phytother Res. (in press).
20. Takara K, Sakaeda T, Okumura K. 2006. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286.
21. Vorobiof DA, Rapoport BL, Chasen MR et al. 2004. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. Breast 13: 219-226.
22. Wang Y. 1997. Research progress on chemical constituents, preparative separation and quality of Sophora flavescens. Zhong Cheng Yao Za Zhi 19: 39-41.
23. Xia YF, Ye BQ, Li WD, Wang JG. 2004. Andrographolide attenuates inflammation by inhibition of NF-κB activation through covalent modification of reduced cystine 62 of P50. J Immunol 173: 4207-4217.
24. Xu X, Jiang J. 1998. Progress in the study of antineoplastic activity of Sophora flavescens Ait. and its alkaloids. Zhongguo Zhong Xi Yi Jie He Za Zhi 18: 314-316.
25. Yigitbasi OG, Younes MN, Doan D et al. 2004. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64: 7977-7984.
26. Zanetta G, Fei F, Mangioni C. 2000. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol 27: 23-27.
27. Zhao YY, Zhang RY. 1991. Research on chemical constituents of Sophora flavescens. Nat Prod Res Dev 3: 93-103.